Jamaica
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.49 (0.11 - 1.41) | 2015 | Modelled | WHO |
| 5 (2.40 - 5.70) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 3.76 (2.65 - 5.29) | 2013 | Modelled | Schweitzer et al, 2015 |
| 0.27 (0.24 - 0.30) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.29 (0.26 - 0.33) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.3 (0.26 - 0.33) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.3 (0.27 - 0.34) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.31 (0.27 - 0.35) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.32 (0.28 - 0.36) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.32 (0.28 - 0.36) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.33 (0.29 - 0.37) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.34 (0.30 - 0.38) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.35 (0.30 - 0.39) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.35 (0.31 - 0.40) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.36 (0.31 - 0.40) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.37 (0.32 - 0.42) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.37 (0.32 - 0.43) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.38 (0.32 - 0.44) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.38 (0.33 - 0.44) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.39 (0.33 - 0.44) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.39 (0.34 - 0.45) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.4 (0.34 - 0.45) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.4 (0.34 - 0.46) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.4 (0.35 - 0.46) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.4 (0.35 - 0.47) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.41 (0.35 - 0.47) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.41 (0.35 - 0.47) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.41 (0.35 - 0.48) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.42 (0.35 - 0.48) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.42 (0.36 - 0.49) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.42 (0.36 - 0.49) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.43 (0.36 - 0.50) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.43 (0.37 - 0.50) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.29 (0.25 - 0.32) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.16 (0.04 - 0.51) | 2015 | Modelled | WHO |
| 0.01 (0.01 - 0.02) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.02 (0.01 - 0.02) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.02 (0.01 - 0.02) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.02 (0.01 - 0.02) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.02 (0.01 - 0.02) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.02 (0.01 - 0.03) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.02 (0.01 - 0.03) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.02 (0.02 - 0.03) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.02 (0.02 - 0.03) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.03 (0.02 - 0.03) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.03 (0.02 - 0.04) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.03 (0.02 - 0.04) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.03 (0.02 - 0.04) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.04 (0.03 - 0.05) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.05 (0.03 - 0.06) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.05 (0.04 - 0.07) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.08 (0.06 - 0.10) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.12 (0.09 - 0.16) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.17 (0.13 - 0.23) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.22 (0.16 - 0.30) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.24 (0.17 - 0.33) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.25 (0.18 - 0.33) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.25 (0.18 - 0.34) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.25 (0.18 - 0.34) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.25 (0.18 - 0.34) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.26 (0.18 - 0.34) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.26 (0.18 - 0.34) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.26 (0.18 - 0.35) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.27 (0.18 - 0.35) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.27 (0.19 - 0.36) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.27 (0.19 - 0.36) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.55 (0.37 - 0.79) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 143,000 (69,000 - 164,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 7,546 (6,629 - 8,503) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 7,841 (6,899 - 8,798) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7,881 (6,934 - 8,823) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7,963 (6,964 - 8,960) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,190 (7,223 - 9,189) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,380 (7,366 - 9,498) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,447 (7,422 - 9,539) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,618 (7,543 - 9,683) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8,834 (7,773 - 9,916) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,030 (7,954 - 10,185) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,134 (7,974 - 10,392) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,228 (8,049 - 10,410) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,410 (8,161 - 10,622) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,619 (8,259 - 10,916) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,792 (8,369 - 11,166) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,863 (8,407 - 11,320) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,886 (8,473 - 11,291) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,946 (8,494 - 11,322) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10,015 (8,597 - 11,419) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10,064 (8,622 - 11,536) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10,060 (8,619 - 11,641) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10,018 (8,603 - 11,535) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,976 (8,562 - 11,464) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,934 (8,503 - 11,451) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,889 (8,463 - 11,423) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,842 (8,417 - 11,374) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,802 (8,357 - 11,366) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,776 (8,328 - 11,328) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,766 (8,280 - 11,343) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,772 (8,310 - 11,388) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,798 (8,338 - 11,412) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 1.2 (0.86 - 1.62) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1.66 (1.34 - 2.05) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.57 (1.26 - 1.94) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.57 (1.25 - 1.98) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.57 (1.22 - 2) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.52 (1.15 - 1.97) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.41 (1.06 - 1.84) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.4 (1.07 - 1.82) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.35 (1.04 - 1.73) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.31 (1.04 - 1.65) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.27 (1.02 - 1.61) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.2 (0.96 - 1.51) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.21 (0.97 - 1.52) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.21 (0.97 - 1.50) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.17 (0.95 - 1.44) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.07 (0.86 - 1.33) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.1 (0.89 - 1.36) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.05 (0.84 - 1.31) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.23 (0.98 - 1.53) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.43 (1.15 - 1.77) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.33 (1.08 - 1.62) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.5 (1.21 - 1.86) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.41 (1.14 - 1.74) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.23 (1 - 1.51) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.15 (0.94 - 1.42) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.17 (0.94 - 1.45) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.17 (0.87 - 1.53) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.15 (0.90 - 1.47) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.15 (0.89 - 1.50) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.2 (0.86 - 1.62) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.18 (0.86 - 1.57) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 96 | 2019 | Survey/reported | WHO/UNICEF |
| 95 | 2020 | Survey/reported | WHO/UNICEF |
| 89 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Planned for 2020
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.71 (1.38 - 2.13) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.69 (1.36 - 2.10) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.68 (1.35 - 2.08) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.65 (1.33 - 2.05) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.63 (1.32 - 2.01) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.62 (1.31 - 2.01) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.62 (1.30 - 2) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.62 (1.30 - 2) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.62 (1.29 - 2) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.61 (1.29 - 2) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.61 (1.29 - 1.99) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.61 (1.29 - 1.99) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.6 (1.30 - 1.98) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.6 (1.29 - 1.98) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.6 (1.29 - 1.99) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.6 (1.29 - 1.99) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.61 (1.30 - 2) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.63 (1.31 - 2.02) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.64 (1.31 - 2.03) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.64 (1.31 - 2.05) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.63 (1.31 - 2.05) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.62 (1.30 - 2.04) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.61 (1.29 - 2.01) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.6 (1.28 - 2) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.59 (1.27 - 1.99) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.59 (1.28 - 1.98) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.59 (1.28 - 1.98) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.59 (1.28 - 1.98) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.6 (1.28 - 1.99) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.61 (1.29 - 2) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.64 (1.32 - 2.04) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.55 (0.42 - 0.82) | 2019 | Modelled | Dugan et al., 2021 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 36,511 (29,250 - 45,388) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 36,571 (29,200 - 45,513) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 36,748 (29,405 - 45,790) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 37,025 (29,768 - 46,146) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 37,407 (30,044 - 46,641) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 37,917 (30,338 - 47,388) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 38,555 (30,889 - 48,115) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 39,264 (31,460 - 49,041) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 39,988 (32,084 - 49,994) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 40,671 (32,598 - 50,547) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,258 (32,818 - 51,583) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,582 (33,280 - 51,796) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,598 (33,397 - 51,577) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,476 (33,582 - 51,574) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,378 (33,382 - 51,462) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,486 (33,562 - 51,597) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 41,772 (33,738 - 51,913) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 42,045 (33,890 - 52,071) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 42,284 (33,939 - 52,330) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 42,493 (33,888 - 52,558) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 42,716 (34,050 - 52,782) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 42,924 (34,323 - 52,987) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,097 (34,532 - 53,215) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,286 (34,793 - 53,310) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,496 (34,995 - 53,820) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 43,770 (35,403 - 54,042) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 44,456 (35,671 - 55,111) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 45,233 (36,449 - 55,891) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 45,782 (36,821 - 56,709) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 46,340 (37,357 - 57,604) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 46,114 (37,158 - 57,370) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 4,300 (3,300 - 6,400) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 1.93 (1.37 - 2.62) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1.92 (1.52 - 2.39) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.40 - 2.22) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.41 - 2.29) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.84 (1.39 - 2.38) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.81 (1.36 - 2.36) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.71 (1.31 - 2.24) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.73 (1.32 - 2.28) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.68 (1.29 - 2.17) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.64 (1.28 - 2.11) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.64 (1.28 - 2.06) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.57 (1.24 - 1.97) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.59 (1.25 - 2) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.5 (1.20 - 1.88) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.56 (1.24 - 1.95) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.4 (1.11 - 1.76) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.33 (1.04 - 1.68) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.34 (1.04 - 1.67) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.5 (1.18 - 1.89) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.69 (1.32 - 2.11) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.54 (1.22 - 1.92) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.35 - 2.16) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.66 (1.33 - 2.08) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.56 (1.26 - 1.93) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.58 (1.27 - 1.97) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.74 (1.39 - 2.19) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.41 - 2.29) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.86 (1.38 - 2.47) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.40 - 2.39) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.89 (1.36 - 2.56) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.37 - 2.62) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Planned for 2020
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
34
2019
(24 - 45)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
54
2019
(38 - 74)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.55
(%)
2020, latest modelled
(0.37 - 0.79(%))
WHO
Prevalence PWID
No data available
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines